184 related articles for article (PubMed ID: 28794865)
1. Recent advances in acute promyelocytic leukaemia.
Ng CH; Chng WJ
F1000Res; 2017; 6():1273. PubMed ID: 28794865
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis, diagnosis and monitoring of residual disease in acute promyelocytic leukaemia.
Reiter A; Lengfelder E; Grimwade D
Acta Haematol; 2004; 112(1-2):55-67. PubMed ID: 15179005
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukaemia with a novel translocation t(16;17)(q12;p13): a case report.
Bhat H; Geelani S; Rashid M; Bhat T; Qadri M; Bashir N N; Manzoor F; Bhat S; Rather F; Rasool J
Malays J Pathol; 2016 Dec; 38(3):311-313. PubMed ID: 28028302
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
He Y; Li X; Wang D; Zhang E; Hu Y; Wang W; Huang R; Xiao R
J Int Med Res; 2014 Dec; 42(6):1363-73. PubMed ID: 25223426
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
7. A non-classical translocation involving 17q12 (retinoic acid receptor alpha) in acute promyelocytic leukemia (APML) with atypical features.
Corey SJ; Locker J; Oliveri DR; Shekhter-Levin S; Redner RL; Penchansky L; Gollin SM
Leukemia; 1994 Aug; 8(8):1350-3. PubMed ID: 8057672
[TBL] [Abstract][Full Text] [Related]
8. Acute promyelocytic leukemia presenting as a paraspinal mass.
Shah NN; Stonecypher M; Gopal P; Luger S; Bagg A; Perl A
J Community Support Oncol; 2016 Mar; 14(3):126-9. PubMed ID: 27058871
[TBL] [Abstract][Full Text] [Related]
9. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
10. Role of Prophylactic Steroids in Differentiation Syndrome.
Sultana J; Dutta J; Mustarin S; Dey P; Roy A; Mamoon MY
Cureus; 2022 Sep; 14(9):e29531. PubMed ID: 36312659
[TBL] [Abstract][Full Text] [Related]
11. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
Mi JQ; Chen SJ; Zhou GB; Yan XJ; Chen Z
J Intern Med; 2015 Dec; 278(6):627-42. PubMed ID: 26058416
[TBL] [Abstract][Full Text] [Related]
12. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
13. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
14. A complex variant t(3;15) (q26;q13) representing cryptic/masked acute promyelocytic leukaemia with a novel breakpoint of chromosome 15-a case report.
Appachu S; Obulareddy C; Sirsath NT; Lakshmaiah KC; Kumari P
Ecancermedicalscience; 2013; 7():340. PubMed ID: 24009642
[TBL] [Abstract][Full Text] [Related]
15. Treatment related acute promyelocytic leukemia (t-APML) in breast cancer survivor treated with anthracycline based chemotherapy: rare case report.
Madabhavi I; Modi G; Panchal H; Patel A; Anand A; Parikh S
Int J Hematol Oncol Stem Cell Res; 2015 Oct; 9(4):215-7. PubMed ID: 26865933
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.
Lee GY; Christina S; Tien SL; Ghafar AB; Hwang W; Lim LC; Lim TH
Cancer Genet Cytogenet; 2005 Jun; 159(2):129-36. PubMed ID: 15899384
[TBL] [Abstract][Full Text] [Related]
18. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure.
Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H
Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868
[TBL] [Abstract][Full Text] [Related]
19. Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Hasan SK; Lo-Coco F
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10 Suppl 3():S139-43. PubMed ID: 21115433
[TBL] [Abstract][Full Text] [Related]
20. Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Tang Y; Wang Y; Hu L; Meng F; Xu D; Wan K; Huang L; Li C; Zhou J
Int J Clin Exp Pathol; 2015; 8(11):15294-300. PubMed ID: 26823883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
